Pharmacologic Topics
Active Resources: 8
-
The National HIV Curriculum (NHC) offers free online continuing education for novice-to-expert health professionals, students, and faculty.
Type: Online and Self-Paced LearningPublish Date: 9/14/2020 -
Excerpt from the Guidelines Introduction: "The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) is a working group of
Type: GuidelinesPublish Date: 12/18/2019 -
Type: Clinical Reference ToolsPublish Date: 6/1/2019Review Date: 10/22/2019 -
This glossary of HIV/AIDS-related terms includes brief lay-oriented descriptions and illustrations. Materials are in the public domain and may be used freely.
Type: Clinical Reference ToolsPublish Date: 2/20/2019Review Date: 2/20/2019 -
Northeast/Caribbean (NECA) AETC offers online continuing education accredited videos and monographs.
Type: Online and Self-Paced LearningPublish Date: 2/5/2019Review Date: 6/11/2021 -
Type: Clinical Reference ToolsPublish Date: 1/15/2019 -
This chart was developed to facilitate continuity of care for people living with HIV who may receive care in both the United States and Mexico.
Type: Clinical Reference ToolsPublish Date: 6/20/2018 -
This guide is designed to assist health professionals in evaluating medical and dental considerations for treating people with HIV in the era of ART.
Type: Clinical Reference ToolsPublish Date: 3/12/2018
Archive Resources: 4
-
Objectives
- Identify issues associated with treating older individuals with HIV infection
Type: Online and Self-Paced LearningPublish Date: 12/7/2016 -
Infographic outlines the purpose and methodology for integrating HIV care into interprofessional education (IPE), and identifies how the AETC Program is helping to facilitate this training through
Type: Clinical Reference ToolsPublish Date: 7/28/2016Review Date: 5/5/2021 -
SAMHSA provides resources related to Medication-Assisted Treatment (MAT) for the treatment of substance use disorders. MAT is the use of medications, in combination with counseling and behavi
Type: Training MaterialsPublish Date: 6/24/2015 -
AETC HIV and Aging Workgroup
HIV and Aging ToolkitType: Clinical Reference ToolsPublish Date: 4/1/2015
Articles: 11
-
Long-Acting Injectable ART: Cabotegravir + Rilpivirine
At CROI 2019, investigators presented 48-week results from the Phase 3 international multisite ATLAS and FLAIR studies of long-acting 2-drug injectable therapy. The study regimen consisted of the integrase inhibitor cabotegravir (CAB) plus the NNRTI rilpivirine (RPV), both given every 4 weeks as...
-
Doravirine--New NNRTI Approved by FDA
The U.S. Food and Drug Administration has approved the NNRTI doravirine for use in initial HIV therapy. FDA approval was based on 48-week results of 2 Phase III studies in treatment-naive persons that showed doravirine + 2 NRTIs resulted in similar rates of viral suppression at 48 weeks as...
-
Tenofovir Alafenamide (TAF) and Darunavir/Cobicistat in Pregnant Women
Two pharmacokinetic studies from AIDS 2018 help elucidate the disposition of tenofovir alafenamide (TAF) and cobicistat-boosted darunavir during pregnancy.
The IMPAACT P1026s study examined plasma concentrations of TAF with and without cobicistat in 43 pregnant women. For women taking...
-
Possible Safety Issue with Dolutegravir during Pregnancy: Reports of Neural Tube Defects
On May 18, 2018, the U.S. Food and Drug Administration and the World Health Organization announced that cases of neural tube defects have been reported in babies of women with HIV who were on treatment with dolutegravir at the time of conception and during early pregnancy. The...
-
Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)
Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain...
-
Doravirine in Initial Therapy: DRIVE-AHEAD Study
Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the...
-
On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen
The EMERALD Study is a Phase 3 randomized (2:1), open-label, noninferiority study examining the strategy of switching patients with suppressed HIV RNA on a regimen consisting of a boosted protease inhibitor plus tenofovir disoproxil fumarate (TDF)/emtricitabine to an investigational single-...
-
Bictegravir in Initial Therapy
Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG)...
-
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy
Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...
-
Switching from TDF/FTC to TAF/FTC
Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...
-
Tissue Levels of TAF: Too Low for PrEP?
There was a pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February. It evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue. Also in anogenital fluid samples after administration of oral...
-
May 18HIV Vaccine Awareness DayEvent type: Awareness Days